US3985875A
Expired / Lapsed
US
⏱️ 0.0 years remaining
ω-(N-acylamino)alkylphosphoryl ethanolamines, pharmaceutical compositions containing them, and their uses
Assignee: Sumitomo Pharma Co Ltd
•
Filing: 1974-12-30
•
Granted: 1976-10-12
•
Expires: 1994-12-30
Abstract
Abstract New omega -(N-acylamino)alkylphosphoryl ethanolamines and their pharmaceutically acceptable acid addition salts have superior renin-inhibitory activities, antihypertensive activities and cholesterol-lowering activities. The omega -(N-acylamino)alkylphosphoryl ethanolamines are prepared by (1) reacting an omega -(N-acylamino) alkanol with a 2-(N-substituted amino)ethyl phosphate or its derivative, hydrolyzing the resulting product or splitting off the phosphoric acid-protective group of the resulting product thereby to form an omega -(N-acylamino) alkyl 2-(N-substituted amino) ethyl phosphate, and splitting off the amino-protective groups of the resulting phosphate, or (2) reacting an omega -(N-acylamino) alkanol with a phosphorus oxyhalide, reacting the resulting omega -(N-acylamino)alkyl dichlorophosphate with a 2-(N-substituted amino) ethanol, hydrolyzing the reaction product to form an omega -(N-acylamino) alkyl 2-(N-substituted)ethyl phosphate, and splitting off the amino-protective groups of said phosphate.
Inventors
- 👤 Kouji Hayashi
- 👤 Masahisa Hashimoto
- 👤 Kiyoshi Nakamura
- 👤 Masanao Shimizu
- 👤 Naonobu Hatano
- 👤 Kunihiko Takeyama
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-30 22:59
CPC Classifications
C; C07; C07F; C07F9/00; C07F9/02; C07F9/06; C07F9/08; C07F9/09; C07F9/091; Y; Y02; Y02P; Y02P20/00; Y02P20/50; Y02P20/55; Y10; Y10S; Y10S530/00; Y10S530/86
Claims Analysis
Total Claims: 29
Claim 1
Independent Claim
28 words
ω-(N-Acylamino)alkylphosphoryl ethanolamines of the general formula ##EQU1## wherein R is octadeca-9,12-dienoyl, octadeca-9,12,15-trienoyl, 4-(4'-chlorophenoxy)phenoxyacetyl or α-[4-(4'-chlorophenoxy)phenoxy]propionyl, and m is 2 or 3, or their pharmaceutically acceptable acid addition salts.
Claim 2
Dependent Claim
28 words
ω-(N-Acylamino)alkylphosphoryl ethanolamines of the general formula ##EQU1## wherein R is octadeca-9,12-dienoyl, octadeca-9,12,15-trienoyl, 4-(4'-chlorophenoxy)phenoxyacetyl or α-[4-(4'-chlorophenoxy)phenoxy]propionyl, and m is 2 or 3, or their pharmaceutically acceptable acid addition salts.
Claim 3
Dependent Claim
19 words
The ω-(N-acylamino)alkylphosphoryl ethanolamines or their pharmaceutically acceptable acid addition salts of claim 1 wherein R is octadeca-9,12-dienoyl or octadeca-9,12,15-trienoyl.
Claim 4
Dependent Claim
20 words
The ω-(N-acylamino)alkylphosphoryl ethanolamines or their pharmaceutically acceptable acid addition salts of claim 1 wherein R is 4-(4'-chlorophenoxy)phenoxyacetyl or α-[4-(4'-chlorophenoxyphenoxy] propionyl.
Claim 5
Dependent Claim
9 words
3-(Octadeca-9,12,15-trienoylamino)propylphosphoryl ethanolamine or its pharmaceutically acceptable acid addition salts.
Claim 6
Dependent Claim
9 words
3-(Octadeca-9,12,15-trienoylamino)propylphosphoryl ethanolamine or its pharmaceutically acceptable acid addition salts.
Claim 7
Dependent Claim
9 words
3-(Octadeca-9,12-dienoylamino)propylphosphoryl ethanolamine or its pharmaceutically acceptable acid addition salts.
Claim 8
Dependent Claim
9 words
3-(Octadeca-9,12-dienoylamino)propylphosphoryl ethanolamine or its pharmaceutically acceptable acid addition salts.
Claim 9
Dependent Claim
9 words
2-[4-(4'-chlorophenoxy)phenoxyacetylamino]ethylphosphoryl ethanolamine or its pharmaceutically acceptable acid addition salts.
Claim 10
Dependent Claim
9 words
2-[4-(4'-chlorophenoxy)phenoxyacetylamino]ethylphosphoryl ethanolamine or its pharmaceutically acceptable acid addition salts.
Claim 11
Dependent Claim
10 words
2-{α-[4-(4'-chlorophenoxy)phenoxy]propionylamino} ethylphosphoryl ethanolamine or its pharmaceutically acceptable acid addition salts.
Claim 12
Dependent Claim
10 words
2-{α-[4-(4'-chlorophenoxy)phenoxy]propionylamino} ethylphosphoryl ethanolamine or its pharmaceutically acceptable acid addition salts.
Claim 13
Dependent Claim
60 words
A pharmaceutical composition for the prevention and treatment of hypertension comprising a mixture of the ω-(N-acylamino) alkylphosphoryl ethanolamine or its pharmaceutically acceptable acid addition salt, as defined in claim 1, as an active ingredient, and a pharmaceutically acceptable carrier wherein the amount of said active ingredient is about 10 to 1500 mg in terms of a dosage unit per day.
Claim 14
Dependent Claim
32 words
The pharmaceutical composition of claim 8 in a form adaptable for oral administration wherein the amount of said active ingredient is 100 to 1500mg in terms of a dosage unit per day.
Claim 15
Dependent Claim
34 words
The pharmaceutical composition of claim 8 in a form adaptable for parenteral administration wherein the amount of said active ingredient is about 10 to 150 mg in terms of a dosage unit per day.
Claim 16
Dependent Claim
21 words
The pharmaceutical composition of claim 8 wherein said active compound is 3-(octadeca-9,12,15-trienoylamino)propylphosphoryl ethanolamine or a pharmaceutically acceptable acid addition salt thereof.
Claim 17
Dependent Claim
23 words
The pharmaceutical composition of claim 8 wherein said active compound is 3-(octadeca-9, 12-dienoylamino) propylphosphoryl ethanolamine or a pharmaceutically acceptable acid addition salt thereof.
Claim 18
Dependent Claim
23 words
The pharmaceutical composition of claim 8 wherein said active compound is 2-[4-(4'-chlorophenoxy)phenoxyacetylamino] ethyl phosphoryl ethanolamine or a pharmaceutically acceptable acid addition salt thereof.
Claim 19
Dependent Claim
25 words
The pharmaceutical composition of claim 8 wherein said active compound is 2-{α-[4-(4'-chlorophenoxy) phenoxy] propionyl amino} ethylphosphoryl ethanolamine or a pharmaceutically acceptable acid addition salt thereof.
Claim 20
Dependent Claim
54 words
A method for treating hypertension in humans which comprises orally administering to said human from about 2 to 30 mg per kilogram of body weight per day of the ω-(N-acylamino) alkylphosphoryl ethanolamine or its pharmaceutically acceptable acid addition salt, as defined in claim 1, either alone or in admixture with a pharmaceutically acceptable carrier.
Claim 21
Dependent Claim
24 words
The method of claim 15 wherein said ω-(N-acylamino) alkyl-phosphoryl ethanolamine is 3-(octadeca-9, 12, 15-trienoylamino) propylphosphoryl ethanolamine or a pharmaceutically acceptable acid addition salt thereof.
Claim 22
Dependent Claim
23 words
The method of claim 15 wherein said ω-(N-acylamino) alkyl-phosphoryl ethanolamine is 3-(octadeca-9, 12-dienoylamino) propylphosphoryl ethanolamine or a pharmaceutically acceptable acid addition salt thereof.
Claim 23
Dependent Claim
24 words
The method of claim 15 wherein said ω-(N-acylamino) alkyl-phosphoryl ethanolamine is 2-[ 4-(4'-chlorophenoxy)phenoxyacetylamino] ethyl phosphoryl ethanolamine or a pharmaceutically acceptable acid addition salt thereof.
Claim 24
Dependent Claim
26 words
The method of claim 15 wherein said ω-(N-acylamino) alkyl-phosphoryl ethanolamine is 2-{α-[4-(4'-chlorophenoxy) phenoxy] propionyl amino } ethylphosphoryl ethanolamine or a pharmaceutically acceptable acid addition salt thereof.
Claim 25
Dependent Claim
53 words
A method for treating hypertension in humans which comprises parenterally administering to said human from about 0.2 to 3 mg per kilogram of body weight per day of the ω-(N-acylamino)alkylphosphoryl ethanolamine or its pharmaceutically acceptable acid addition salt, as defined in claim 1, either alone or in admixture with a pharmaceutically acceptable carrier.
Claim 26
Dependent Claim
24 words
The method of claim 20 wherein said ω-(N-acylamino) alkyl-phosphoryl ethanolamine is 3-(octadeca-9, 12, 15-trienoylamino) propylphosphoryl ethanolamine or a pharmaceutically acceptable acid addition salt thereof.
Claim 27
Dependent Claim
23 words
The method of claim 20 wherein said ω-(N-acylamino) alkyl-phosphoryl ethanolamine is 3-(octadeca-9, 12-dienoylamino) propylphosphoryl ethanolamine or a pharmaceutically acceptable acid addition salt thereof.
Claim 28
Dependent Claim
23 words
The method of claim 20 wherein said ω-(N-acylamino) alkyl-phosphoryl ethanolamine is 2-[4-(4'chlorophenoxy)phenoxyacetylamino] ethyl phosphoryl ethanolamine or a pharmaceutically acceptable acid addition salt thereof.
Claim 29
Dependent Claim
25 words
The method of claim 20 wherein said ω-(N-acylamino) alkyl-phosphoryl ethanolamine is 2-{ α-[4-(4'-chlorophenoxy)phenoxyl] propionyl amino} ethylphosphoryl ethanolamine or a pharmaceutically acceptable acid addition salt thereof.
References Cited (Backward Citations)
US3577446A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1979-10-12 | 1980-04-12 | 1980-10-12 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1983-10-12 | 1984-04-12 | 1984-10-12 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1987-10-12 | 1988-04-12 | 1988-10-12 | $7700.00 | Window Closed / Lapsed |